ZimVie completes acquisition by ARCHIMED, becomes privately held.

ZimVie Inc., a global life sciences leader in the dental implant market, has been acquired by ARCHIMED, an investment firm focused on healthcare. ARCHIMED acquired all outstanding shares of ZimVie stock for $19 per share, and the company is now privately held. The transaction was completed on October 20, 2025, and ZimVie's common stock no longer trades on the NASDAQ stock exchange.

On October 20, 2025, ARCHIMED, a leading healthcare-focused investment firm, completed its acquisition of ZimVie Inc., a global leader in the dental implant market. The transaction involved ARCHIMED acquiring all outstanding shares of ZimVie stock for $19.00 per share in cash, effective immediately, according to a QuiverQuant report.

ZimVie, headquartered in Palm Beach Gardens, Florida, is known for its comprehensive portfolio of dental implant products and solutions. The acquisition positions ZimVie to accelerate its growth under ARCHIMED's strategic support. ARCHIMED's Managing Partner, André-Michel Ballester, expressed enthusiasm about the partnership, highlighting the alignment of ZimVie’s innovation and brand with ARCHIMED’s mission in healthcare, as noted in the QuiverQuant report.

The acquisition was advised by financial and legal experts from Centerview Partners and Cravath, Swaine & Moore LLP for ZimVie, while UBS Investment Bank and Latham & Watkins LLP advised ARCHIMED. The transaction has significant implications for ZimVie's stockholders, who will no longer see their shares traded on NASDAQ, a detail also described in the QuiverQuant report.

The acquisition suggests potential strategic benefits for ZimVie, including access to ARCHIMED's operational and financial resources, which could drive innovation and expansion in product offerings. However, the move also raises concerns about ZimVie's previous independence and visibility as a publicly traded company, an issue the QuiverQuant report discussed.

Institutional investors have been active in ZimVie's stock, with 86 adding shares and 83 decreasing their positions in the most recent quarter. Analysts have also issued price targets, with a median target of $14.5, suggesting varying opinions on the acquisition's impact, according to a StockTitan article.

ARCHIMED, with offices in Europe, North America, and Asia, manages €8 billion across various healthcare investments. The firm's expertise aligns well with ZimVie's goals, potentially leading to significant growth opportunities in the dental implant market, the QuiverQuant report added.